OPTH Optimi Health Corp.
Price Chart
Executive Summary
Optimi Health Corp. announced completion of a GMP production run of 5mg psilocybin capsules, the same formulation already prescribed commercially for treatment-resistant depression in Australia. Additional product from this run is earmarked for planned clinical trials in the U.S. and Europe. The filing is a routine operational update with no financial data, and the forward-looking statements about future trials and market expansion are not backed by concrete milestones or revenue figures.
Actionable Insight
Monitor for future announcements regarding clinical trial initiation in the U.S. or Europe, which could serve as a catalyst. Without revenue or guidance data, this filing alone does not provide a trading signal.
Key Facts
- Completed GMP production run of 5mg psilocybin finished drug product.
- Same formulation already prescribed commercially in Australia for treatment-resistant depression.
- Additional product earmarked for planned clinical trials in the U.S. and Europe.
- All manufacturing stages completed in-house under Health Canada Drug Establishment Licence.
- Facility includes a Health Canada compliant Level 8 vault with capacity to store controlled substances valued at up to C$100 million.
- Authorized to hold up to 20 kg of psilocybin and approximately 2,000 kg of biomass on site.
Financial Impact
No financial figures disclosed; no revenue, deal value, or offering size provided.
Risk Factors
- Forward-looking statements about clinical trials and market expansion are subject to regulatory approvals and may not materialize.
- No financial data provided; commercial revenue from Australia is not quantified.
- Psychedelic drug sector remains highly regulated and speculative.
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001193125-26-252513 |
| Document: d113735d6k.htm | 0001193125-26-252513 |
| Document: 0001193125-26-252513-index-headers.html | 0001193125-26-252513 |
| Document: 0001193125-26-252513-index.html | 0001193125-26-252513 |
| Document: 0001193125-26-252513.txt | 0001193125-26-252513 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 10, 2026
2d ago
|
6-K
| $4.77 awaiting T+1 | awaiting T+1 | — | $4.55 (−4.61%) |
|
Jun 8, 2026
4d ago
|
6-K
| $5.23 awaiting T+1 | awaiting T+1 | — | $4.55 (−13.00%) |
|
Jun 2, 2026
10d ago
|
6-K
| $5.85 $5.67 | ▼ −3.08% | ▼ −2.36% | $4.55 (−22.22%) |
|
May 29, 2026
14d ago
|
6-K
| $5.97 $5.64 | ▼ −5.53% | ▼ −5.80% | $4.55 (−23.79%) |
|
May 29, 2026
14d ago
|
Press Release
| $5.97 $5.64 | ▼ −5.53% | ▼ −5.80% | $4.55 (−23.79%) |
|
Mar 24, 2026
11w ago
|
F-1/A
| — | awaiting T+1 | — | — |
|
Mar 13, 2026
13w ago
|
F-1/A
| — | awaiting T+1 | — | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access